Upregulation of PD-L1. Demonstrated marked antitumor efficacy compared with monotherapy in preclinical ALK-positive NSCLC models. In clinical trials, combinations showed some activity but with severe adverse events. Here, ALK is linked to non-small cell lung carcinoma.